Login
Companies $NMRA
$0.40 +$0.03 (7.63%) After hours
Neumora Therapeutics, Inc. logo

Neumora Therapeutics, Inc.

neumoratx.com

What Do They Do?

Develops investigational medicines for people with depression, Alzheimer’s disease agitation, schizophrenia, obesity and other brain-related disorders.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +39% (Loss)
vs −$56.8M in Q3 FY2025
  • Oct 26, 2026 Nasdaq notified Neumora it did not meet the minimum bid price requirement The company has until April 26, 2027, to regain compliance.
  • Aug 14, 2026 Joshua Pinto became CEO as Paul Berns became Executive Chair The leadership transition took effect August 14, 2026.
  • Jun 10, 2026 Neumora discontinued navacaprant development after Phase 3 studies missed endpoints The company also announced a workforce reduction of approximately 35%.

Who Do They Compete With?

Competes with Axsome Therapeutics, Denali Therapeutics, Neurocrine Biosciences, Prothena, and Xenon Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support